C4 Therapeutics (NASDAQ:CCCC – Get Free Report) and Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.
Risk & Volatility
C4 Therapeutics has a beta of 2.93, suggesting that its share price is 193% more volatile than the S&P 500. Comparatively, Arcturus Therapeutics has a beta of 2.24, suggesting that its share price is 124% more volatile than the S&P 500.
Institutional & Insider Ownership
78.8% of C4 Therapeutics shares are held by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are held by institutional investors. 8.7% of C4 Therapeutics shares are held by insiders. Comparatively, 15.3% of Arcturus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| C4 Therapeutics | 1 | 2 | 6 | 0 | 2.56 |
| Arcturus Therapeutics | 1 | 4 | 7 | 0 | 2.50 |
C4 Therapeutics presently has a consensus price target of $7.25, indicating a potential upside of 232.57%. Arcturus Therapeutics has a consensus price target of $35.75, indicating a potential upside of 403.52%. Given Arcturus Therapeutics’ higher probable upside, analysts plainly believe Arcturus Therapeutics is more favorable than C4 Therapeutics.
Earnings & Valuation
This table compares C4 Therapeutics and Arcturus Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| C4 Therapeutics | $35.58 million | 5.94 | -$105.32 million | ($1.67) | -1.31 |
| Arcturus Therapeutics | $85.14 million | 2.37 | -$80.94 million | ($2.46) | -2.89 |
Arcturus Therapeutics has higher revenue and earnings than C4 Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares C4 Therapeutics and Arcturus Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| C4 Therapeutics | -395.51% | -64.40% | -38.69% |
| Arcturus Therapeutics | -68.35% | -28.68% | -21.05% |
Summary
Arcturus Therapeutics beats C4 Therapeutics on 9 of the 14 factors compared between the two stocks.
About C4 Therapeutics
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
About Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Receive News & Ratings for C4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
